Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $19,646.22 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,266 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $19,646.22. Following the completion of the sale, the general counsel now directly owns 33,510 shares in the company, valued at $290,531.70. This trade represents a 6.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK traded up $0.07 during mid-day trading on Thursday, hitting $8.33. 1,070,583 shares of the stock were exchanged, compared to its average volume of 833,189. The company has a market cap of $441.22 million, a P/E ratio of -3.97 and a beta of 0.99. The stock’s fifty day simple moving average is $9.50 and its two-hundred day simple moving average is $11.51. Stoke Therapeutics, Inc. has a twelve month low of $5.60 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STOK has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Chardan Capital reissued a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $23.00.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System increased its holdings in shares of Stoke Therapeutics by 16.2% in the fourth quarter. California State Teachers Retirement System now owns 32,068 shares of the company’s stock valued at $354,000 after purchasing an additional 4,468 shares in the last quarter. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Stoke Therapeutics by 123.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company’s stock valued at $1,053,000 after purchasing an additional 52,813 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Stoke Therapeutics by 6.7% in the fourth quarter. Squarepoint Ops LLC now owns 120,242 shares of the company’s stock valued at $1,326,000 after purchasing an additional 7,575 shares in the last quarter. Finally, Tang Capital Management LLC acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $3,309,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.